

44 (New). A process according to claim 15, wherein the R^1 C_1-C_6 alkyl group is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl and isomers thereof.

45 (New). A polymer according to claim 12 wherein the anti-cancer agent is doxorubicin, daunomycin, or paclitaxel.

46 (New). A polymer according to claim 13 wherein Q is 2-hydroxypropylamino.

47 (New). A process according to claim 8, wherein R^4 is an aminoacyl group or an oligopeptidyl group and Z is 2 to 6 aminoacyl groups.

48 (New) The polymer according to claim 1, wherein X is selected from the group consisting of N-succinimidyl, pentachlorophenyl, pentafluorophenyl, para-nitrophenyl, dinitrophenyl, N-phthalimido, N-norbornyl, cyanomethyl, pyridyl, trichlorotriazine, 5-chloroquinilino, and imidazole, and R is hydrogen or methyl.

JBH
5-26-04 49 (New). The polymer according to claim 1, wherein the molecular weight (Mw) is in the range 25,000-40,000.

50 (New). The polymer according to claim 1, wherein the polydispersity is less than 1.2.

51 (New). A composition comprising a polymer as defined in claim 50 having a molecular weight (Mw) in the range 25,000-40,000 and a pharmaceutically acceptable excipient.